Ponvory®
Quick Facts
Ponvory® reduces the number of white blood cells, immune cells called lymphocytes, thereby reducing nerve damage.
Tablet taken orally
Once per day
Relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting MS, and active secondary-progressive MS
Potential Benefit:
Compared to an active comparator over a 108-week the OPTIMUM study:
- 30.5% lower annual relapse rate
- 59% reduction in new gadolinium-enhancing (GdE) T1 lesions and 56% reduction in the number of new or enlarging T2 lesions
- Worsening disability was prevented for most people
Common Potential Side Effects
Upper respiratory tract infections, elevated liver enzymes, high blood pressure
Prescription Assistance:
For assistance finding additional resources that might help cover the costs of your prescription, contact MSAA.
DRUGMAKER
Janssen
HOW Ponvory® WORKS
Ponvory® is thought to trap the number of white blood cells (immune cells) called ‘lymphocytes’ in the lymph nodes, thereby reducing the number of white blood cells that get sent to the nervous system. This helps helps reduce nerve damage.
FDA-Approved
Ponvory® was FDA approved in 2021 to treat relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary-progressive disease, in adults.
Potential Side Effects
Upper respiratory tract infections, elevated liver enzymes, and high blood pressure. Adverse effects can include more serious infections and a slowed heart rate (bradycardia or bradyarrhythmia), macular edema (swelling behind the eye), as well as skin cancer.
OTHER KEY INFORMATION
Healthcare professionals may perform several tests before starting Ponvory to determine if first-dose monitoring is necessary and to determine appropriate monitoring while on treatment.
Testing completed prior to starting Ponvory® includes: Pre-testing is required, including CBC, liver function studies, cardiac evaluation to include EKG, ophthalmology evaluation, and varicella testing.
CBC and liver function studies should be repeated periodically. (How frequently they should be repeated is not specified but should be done at least yearly.) Ophthalmology evaluations may be repeated as clinically indicated.
When starting Ponvory, please note there is a titration period (starting at a smaller dose and increasing over successive weeks).